Pulmonary vasodilation by sildenafil in acute intermediate-high risk pulmonary embolism: a randomized explorative trial
Authors:
Open Access
- 28 February 2021
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 21 (1) , 1-8
Abstract
Background: To investigate if acute pulmonary vasodilation by sildenafil improves right ventricular function in patients with acute intermediate-high risk pulmonary embolism (PE). Methods: Single center, explorative trial. Patients with PE were randomized to a single oral dose of sildenafil 50 mg (n = 10) or placebo (n = 10) as add-on to conventional therapy. The time from hospital admission to study inclusion was 2.3 ± 0.7 days. Right ventricular function was evaluated immediately before and shortly after (0.5–1.5 h) randomization by right heart catheterization (RHC), trans-thoracic echocardiography (TTE), and cardiac magnetic resonance (CMR). The primary efficacy endpoint was cardiac index measured by CMR. Results: Patients had acute intermediate-high risk PE verified by computed tomography pulmonary angiography, systolic blood pressure of 135 ± 18 (mean ± SD) mmHg, increased right ventricular/left ventricular ratio 1.1 ± 0.09 and increased troponin T 167 ± 144 ng/L. Sildenafil treatment did not improve cardiac index compared to baseline (0.02 ± 0.36 l/min/m2, p = 0.89) and neither did placebo (0.00 ± 0.34 l/min/m2, p = 0.97). Sildenafil lowered mean arterial blood pressure (− 19 ± 10 mmHg, p < 0.001) which was not observed in the placebo group (0 ± 9 mmHg, p = 0.97). Conclusion: A single oral dose of sildenafil 50 mg did not improve cardiac index but lowered systemic blood pressure in patients with acute intermediate-high risk PE. The time from PE to intervention, a small patient sample size and low pulmonary vascular resistance are limitations of this study that should be considered when interpreting the results. Trial Registration: The trial was retrospectively registered at www.clinicaltrials.gov (NCT04283240) February 2nd 2020, https://clinicaltrials.gov/ct2/show/NCT04283240?term=NCT04283240&draw=2&rank=1.Keywords
All Related Versions
Funding Information
- Novo Nordisk Fonden (NNF16OC0023244)
This publication has 28 references indexed in Scilit:
- Cardiac output and cardiac index measured with cardiovascular magnetic resonance in healthy subjects, elite athletes and patients with congestive heart failureJournal of Cardiovascular Magnetic Resonance, 2012
- No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trialBMC Pulmonary Medicine, 2010
- Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic reviewEuropean Respiratory Journal, 2009
- Massive Pulmonary EmbolismCirculation, 2006
- Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertensionJACC, 2004
- Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effectsEuropean Heart Journal, 2004
- Autopsy‐verified venous thromboembolism within a defined urban population – the city of Malmö, SwedenAPMIS, 1998
- Right ventricular dysfunction after acute pulmonary embolism: Pathophysiologic factors, detection, and therapeutic implicationsAmerican Heart Journal, 1995
- Natural history of pulmonary embolismProgress in Cardiovascular Diseases, 1975
- The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary diseaseThe American Journal of Cardiology, 1971